Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company dedicated to advancing regenerative therapies in immunotherapy endocrinology urology neurology and orthopedics. The company develops platforms that use a patient’s own stem cells or immune cells to treat conditions such as erectile dysfunction type 1 diabetes chronic lower back pain premature ovarian failure and other indications. Its lead platforms include ImmCelz™ a personalized…
Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company dedicated to advancing regenerative therapies in immunotherapy endocrinology urology neurology and orthopedics. The company develops platforms that use a patient’s own stem cells or immune cells to treat conditions such as erectile dysfunction type 1 diabetes chronic lower back pain premature ovarian failure and other indications. Its lead platforms include ImmCelz™ a personalized immune cell therapy AlloStem™ an allogenic perinatal cell line StemSpine® a procedure for disc degeneration OvaStem™ for ovarian function CaverStem® for erectile dysfunction and FemCelz® for female sexual function. These technologies are supported by a portfolio of issued patents and pending applications covering various cell based treatments.
The company currently generates limited revenue from its CaverStem® procedure which treats erectile dysfunction. In recent years it has reported minimal revenue from this product and has paused marketing while it reevaluates the product strategy. Other platforms such as ImmCelz™ AlloStem™ StemSpine® and OvaStem™ remain in preclinical or clinical trial stages and have not yet contributed material sales. Revenue may also arise from licensing agreements or partnership collaborations but these have not been disclosed as significant sources of income.
Creative Medical Technologies Holdings, Inc. occupies a niche within the broader regenerative medicine sector where it competes with larger firms such as Mesoblast Longeveron BioRestorative Therapies and DiscGenics. Its competitive advantages stem from proprietary cell platforms patented procedures and regulatory milestones including FDA cleared investigational new drug applications orphan drug designation for its ImmCelz™ therapy and Fast Track designation for its lead candidate. The company also benefits from a deep intellectual property portfolio with seven issued patents and numerous pending applications that protect its innovations in cell based therapies. These factors position Creative Medical Technologies Holdings, Inc. as a specialized player focused on early stage clinical development rather than a large scale commercial manufacturer.
Creative Medical Technologies Holdings, Inc. serves patients suffering from a range of conditions including erectile dysfunction type 1 diabetes chronic lower back pain premature ovarian failure and other disorders targeted by its regenerative platforms. Therapy is delivered through licensed physicians and clinical trial sites rather than directly to consumers so the customer base comprises medical professionals and research institutions administering the treatments. While specific patient or clinic names are not disclosed the company focuses on individuals with unmet medical needs where existing therapies are limited or ineffective.